GlucoTrack (GCTK) vs Nexalin Technology (NXL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Nexalin Technology is the larger company by market cap ($3.0 million vs $1.0 million), about 2.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GCTK | NXL |
|---|---|---|
| Share price | $1.03 | $3.63 |
| Market cap | $1.05M | $3.01M |
| 1-day change | -7.21% | -11.68% |
| EPS (TTM) | $-123.15 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $50.70 |
| 52-week low | $1.00 | $3.50 |
| Distance from 52-week high | -99.17% | -92.84% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +313.22% |
| Average volume | 2.06M | 1.02M |
| Shares outstanding | 1.02M | 829.40K |
| Employees | 15 | 8 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nexalin Technology is about 2.9 times larger than GlucoTrack by market value ($3.01M vs $1.05M).
About GlucoTrack
GCTK stock →GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Health Care · Medical/Dental Instruments · 15 employees
About Nexalin Technology
NXL stock →Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 8 employees
GCTK vs NXL FAQ
Which is bigger, GlucoTrack or Nexalin Technology?
Nexalin Technology (NXL) is larger, with a market capitalization of $3.01M compared with $1.05M for GlucoTrack (GCTK).
Are GlucoTrack and Nexalin Technology in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for GlucoTrack and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Nexalin Technology.